Annual industry ranking and forecast
Biopharma’s wider visibility in the COVID-19 pandemic response and 2020’s public spotlight on diversity issues bring both challenges and opportunities for industry leaders going forward.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
The global COVID-19 crisis has presented a chance for industry to improve its reputation by highlighting the value of its R&D engines. Pharma executives and observers outline why they are optimistic about a chance to regain public trust.
A change in direction for the French firm means a new approach to R&D. Sanofi’s global head of development and chief medical officer Dietmar Berger talked to In Vivo about what was needed to get the company’s R&D machine back on track.
In Vivo discusses dimensions around pharma CEO pay in India and whether it should be part of cost management efforts amid the pandemic.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.